Calendario›ONC›BGB-58067

BGB-58067

A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants

Ensayo de BeOne Medicines Ltd. en Voluntarios sanos.

Fase

Fase 1

Estado

Reclutando pacientes

Participantes

30

previstos

Centros

1

Fin del objetivo primario

sep 2026

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en jun 2026.

Qué mide

Part A and Part B: Time of the Maximum Observed Concentration (Tmax) of BGB-58067 (Part A: Day 1 and Day 18; Part B: Day 1 and Day 8) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is being done to understand how the body processes the study drug (BGB-58067) when it is taken together with other medicines. BGB-58067 is mainly broken down in the body by a liver enzyme called CYP3A. Some medicines can affect how this enzyme works. For example, certain medicines can increase the production of the enzyme (called inducers), while others can block or inhibit its activity (called inhibitors). This may change how much of the study drug is present in the bloodstream. In this study, we will give BGB-58067 together with two commonly used medicines: * Part A: Phenytoin (inducer), which can increase the production of the enzyme, and * Part B: Itraconazole (inhibitor), which can inhibit the activity of the enzyme.

Más ensayos de ONC

Todos los de ONC, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07590102), actualizada en sep 2026.